Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04948333
Title Asciminib Treatment Optimization in >= 3rd Line CML-CP.
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA | GBR | FRA | ESP | DEU | CAN | AUT

Facility Status City State Zip Country Details
Novartis Investigative Site Caba Buenos Aires C1221ADC Argentina Details
Novartis Investigative Site Buenos Aires C1114AAN Argentina Details
Novartis Investigative Site Graz 8036 Austria Details
Novartis Investigative Site Linz 4010 Austria Details
Novartis Investigative Site Wien 1140 Austria Details
Novartis Investigative Site Rio de Janeiro RJ 20211-030 Brazil Details
Novartis Investigative Site Sao Paulo 01236 030 Brazil Details
Novartis Investigative Site Vancouver British Columbia V5Z 1M9 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Bordeaux 33076 France Details
Novartis Investigative Site Lyon 69373 France Details
Novartis Investigative Site Montpellier cedex 5 34295 France Details
Novartis Investigative Site Nantes Cedex 1 44093 France Details
Novartis Investigative Site Paris 10 75475 France Details
Novartis Investigative Site Mannheim Baden Wuerttemberg 68305 Germany Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Jena 07740 Germany Details
Novartis Investigative Site Kiel 24116 Germany Details
Novartis Investigative Site Muenchen 80377 Germany Details
Novartis Investigative Site Thessaloniki GR 570 10 Greece Details
Novartis Investigative Site Athens 115 27 Greece Details
Novartis Investigative Site Monza MB 20900 Italy Details
Novartis Investigative Site Roma RM 00161 Italy Details
Novartis Investigative Site Verona VR 37126 Italy Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 06351 Korea, Republic of Details
Novartis Investigative Site Taegu 41944 Korea, Republic of Details
Novartis Investigative Site Kota Kinabalu Sabah 88586 Malaysia Details
Novartis Investigative Site Johor Bahru 80100 Malaysia Details
Novartis Investigative Site Penang 10990 Malaysia Details
Novartis Investigative Site Selangor 68000 Malaysia Details
Novartis Investigative Site Muscat 123 Oman Details
Novartis Investigative Site Katowice 40-519 Poland Details
Novartis Investigative Site Warszawa 02 776 Poland Details
Novartis Investigative Site Singapore 119074 Singapore Details
Novartis Investigative Site Singapore 169608 Singapore Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Santiago De Compostela Galicia 15706 Spain Details
Novartis Investigative Site Bilbao Pais Vasco 48013 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Santa Cruz de Tenerife 38009 Spain Details
Novartis Investigative Site Cambridge CB2 2QQ United Kingdom Details
Novartis Investigative Site Leeds LS9 7TF United Kingdom Details
Novartis Investigative Site London SE1 9RT United Kingdom Details
Novartis Investigative Site London W12 0HS United Kingdom Details
Novartis Investigative Site Hanoi 100000 Vietnam Details
Novartis Investigative Site Ho Chi Minh 738000 Vietnam Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field